CraigWalterHendrixMD

PubMed

• Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
  Mark A Marzinke, Kelong Han, Brett Hanscom, Xu Guo, Estelle Piwowar-Manning
  Antimicrobial Agents and Chemotherapy. 2024-11-06
• Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial.
  Stanley E Cooper, Shuaiqi Zhang, Daniel Haines, Kenneth H Mayer, K Rivet Amico
  AIDS and Behavior. 2024-11-01
• 1 citations
  The Global Impact of Diversifying PrEP Options: Results of an International Discrete Choice Experiment of Existing and Potential PrEP Strategies with Gay and Bisexual ...
  Christine Tagliaferri Rael, Rebecca Giguere, Ewa Bryndza Tfaily, Sara Sutton, Elizabeth Horn
  AIDS Research and Human Retroviruses. 2024-10-01

Journal Articles

• Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche  
  Craig W Hendrix, Edward J Fuchs, AIDS and Behavior
• Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Individuals: HPTN 077, a Phase 2a Randomized Controlled Trial  
  Susan H Eshleman, Joseph J Eron, Raphael J Landovitz, Myron S Cohen, Jeremy Sugarman, Mark A Marzinke, Craig W Hendrix, PLoS One
• Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women  
  Craig W Hendrix, Robert A Salata, Mark A Marzinke, Craig J Hoesley, Ian McGowan, Clinical Infectious Diseases
• Safety and Pharmacokinetics of Single, Dual, and Triple Antiretroviral Drug Formulations Delivered by Pod-Intravaginal Rings Designed for HIV-1 Prevention: A Phase I T...  
  Peter A Anton, Trevelyn J Olive, Mark A Marzinke, Rochelle K Rosen, Craig W Hendrix, Kathleen L Vincent, PLoS One
• HIV Antiretroviral Pre‐Exposure Prophylaxis: Development Challenges and Pipeline Promise  
  Craig Hendrix, MD, Clinical Pharmacology & Therapeutics
• Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies  
  Craig W Hendrix, Mark A Marzinke, Ethel Weld, Edward J Fuchs, AIDS and Behavior
• Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic and Vaginal Tissue.  
  Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW, AIDS Res Hum Retroviruses, 5/29/2013
• Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect.  
  Avery LB, Zarr M, Bakshi RP, Siliciano R, Hendrix CW, AIDS Res Hum Retroviruses, 5/22/2013
• Quantitative Assessment of Altered Rectal Mucosal Permeability Due to Rectally Applied Nonoxynol-9, Biopsy, and Simulated Intercourse.  
  Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW, J Infect Dis, 1/13/2013
• Pharmacokinetic cross-over study in women comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other anatomic compartments (MTN-001).  
  Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus N, PLoS One, 1/1/2013
• Protein-free Efavirenz is Equivalent in Cerebrospinal Fluid & Blood Plasma: Applying the Law of Mass Action to Predict Protein-Free Drug Concentration.  
  Avery LB, Sacktor N, McArthur JC, Hendrix CW, Antimicrob Agents Chemother, 1/1/2013
• Antiretroviral Prophylaxis for HIV Infection among People Who Inject Drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial.  
  Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze R, Mc..., Lancet, 1/1/2013
• Phase 0 Study of Intracellular Drug Concentrations: Accelerator Mass Spectrometry Measurement of Phosphorylated Tenofovir and Zidovudine.  
  Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs E, J Acq Immuno Defic Syndr, 12/15/2012
• Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-HIV Drug Maraviroc.  
  Lu, Y, Hendrix CW, Bumpus NN, Drug Metabol Disp, 12/1/2012
• Compartmentalization and Antiviral Effect of Efavirenz Metabolites in Blood Plasma, Seminal Plasma and Cerebrospinal Fluid.  
  Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN, Drug Metabo Disp, 11/19/2012
• RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir DF.  
  AIDS Res Hum Retroviruses, 11/1/2012
• Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.  
  Minnis AM, Gandham S, Richardson BA, Guddera V, Riddler S, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW, AIDS Behav, 10/14/2012
• Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women.  
  Baeten JM, Donnell D, Ndase P, Mugo NR, et al., N Engl J Med, 8/2/2012
• Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana: the TDF2 Study.  
  Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Segolodi TM, Soud FA, Henderson FL, Pathak SR, Rose CE, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde K, Abebe D. Buli..., N Engl J Med, 8/2/2012
• Antiretroviral prophylaxis for HIV prevention in heterosexual men and women  
  Baeten JM1, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquh..., N Engl J Med, 8/2/2012
• Stavudine (d4T) concentrations in women receiving post-partum antiretroviral treatment and their breastfeeding infants.  
  Fogel J, Taha TE, Sun J, Hoover DR, Parsons TL,Kumwenda JJ, Mofenson LM, Fowler MG, Hendrix CW, Kumwenda NI, Eshleman SH, Mirochnick M, JAIDS, 5/18/2012
• Acyclovir achieves lower concentration in African HIV-seronegative, HSV-2 seropositive women compared to non-African populations.  
  Lu Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L, Hendrix CW, Antimicrob Agents Chemother, 5/1/2012
• Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.  
  Nyunt MM, Lu Y, Yu Q, El-Gasim M, Parsons TL, Petty BG, Hendrix CW, Clin Pharmacol Ther, 5/1/2012
• Can we determine who uses? Self reports and objective measures of adherence in microbicide and PrEP trials.  
  Hendrix CW, 4/1/2012
• Quantification of the Spatial Distribution of Rectally Applied Surrogates for Microbicide and Semen in Colon with SPECT Imaging.  
  Cao YJ, Caffo BS, Fuchs EJ, Lee LA, Du Y, Li L, Bakshi RP, Macura K, Khan WA, Wahl RL, Grohskopf LA, Hendrix CW, Br J Clin Pharmaco, 3/9/2012
• Join now to see all

Books/Book Chapters

• Novel Pharmacokinetic Methods for Developing HIV Chemoprevention Strategies. 
  Hendrix CW2005
• Strategies for the Management of HIV/HCV Co-infection. 
  Chapter: Hepatotoxicity of antiretroviral therapy and drug-drug interactions with antiviral therapies for hepatitis C infection. 
  Hendrix CW, Sulkowski MSSeacaucus: Projects in Knowledge2002
• Protecting Data Privacy in Health Services Research. 
  Chapter: Institutional Review Boards and Health Services Research Data Privacy. A Workshop Summary. 
  Committee on the role of institutional review boards in health services research data privacy protection.Institute of Medicine, National Academy Press, Washington, DC2000
• Post-Marketing Surveillance. 
  Hendrix CW1999
• Military AIDS Symposium. 
  Hendrix CW1997
• AIDS: biology, diagnosis, treatment and prevention 
  Chapter: Pharmacology of Antiretroviral Agents. 
  DeVita VT, Hellman S, Rosenberg SALippincott-Raven, Philadelphia, PAEdition 4th,1997
• Join now to see all

Lectures

• Scientific Misconduct. 
  FDA Office of Criminal Investigations. Charleston, SC. - 6/18/2013
• Making sense out of oral and topical PrEP trials: Using little studies to understand big studies. 
  Annual Meeting of HIV Prevention Trials Network, Washington, DC. - 5/6/2013
• Pharmacological Challenges for Next Generation PrEP. 
  14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, Netherlands. - 4/23/2013
• Pharmacological Aspects of PrEP. 
  Hopkins-Brazil HIV conference, Rio de Janeiro, Brazil. - 4/19/2013
• How PK (could) inform PrEP Trials. 
  NIH, Division of AIDS Seminar, Bethesda, MD. - 3/15/2013
• PK Assessment of Adherence in PrEP Trials. 
  Pharmacometrics in Antiviral Drug Development Symposium, Annual Meeting of ASCPT, Indianapolis, IN. - 3/8/2013
• Pharmacometric approaches to adherence assessment in HIV prevention trials. 
  Mercer University Invited talk. Atlanta, GA. - 3/5/2013
• Enriching the design of clinical PK/PD studies of novel drug delivery systems. 
  Bill & Melinda Gates Foundation – NIH Think Tank on HIV Prevention Drug Delivery Systems. Washington - 2/1/2013
• Pharmacological Approach to Monitoring Drug Adherence. 
  Microbicide Trials Network Annual Meeting. Bethesda, MD. - 2/1/2013
• Measuring PK & Adherence in PrEP Trials: Explanation & Prediction. 
  RIHES, Chiang Mai University, Chiang Mai, Thailand. Department of Medicine, University of Malaya, Ku - 1/15/2013
• Clinical Pharmacology Approach to Rational Rectal Microbicide Development. 
  Thai Red Cross/HIV-NAT, Chulalongkorn Univ, Bangkok, Thailand. - 1/10/2013
• A Pharmacological Perspective on HIV Explant Challenge. 
  Biopsy Challenge meeting, NIH-Bill and Melinda Gates Foundation, Washington, DC. - 11/29/2012
• Genital and Anal Tract PrEP Pharmacokinetics. 
  Office of AIDS Research Advisory Council Annual Meeting, Washington, DC. - 11/8/2012
• Pharmacokinetic Assessment of PrEP Adherence. 
  NIH DAIDS Behavioral Science Working Group Data Capture Technologies Focus Group. - 10/11/2012
• Oral & Topical PrEP: Unifying RCT Outcomes. 
  7th HIV Transmission Workshop, Washington, DC. - 6/1/2012
• Making Sense of Oral PrEP trials: Little Studies Informing Big Studies. 
  Plenary Session, HPTN Annual Meeting. Washington, DC. - 6/1/2012
• Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies. 
  Treatment as Prevention/Pre-Exposure Prophylaxis Summit. London, England. - 6/1/2012
• Exploring Outcome Variability Across HIV Pre-Exposure Prophylaxis (PrEP) Trials. 
  Anti-infective Section, ASCPT Annual Meeting. National Harbor, MD. - 3/1/2012
• Clinical Pharmacology in PrEP Development: Can small intensive studies inform RCTs? 
  Microbicide Trials Network Annual Meeting. Bethesda, MD. - 2/1/2012
• Attempts to Improve the Rational Development of HIV Pre-Exposure Prophylaxis through Clinical Pharmacology. 
  Mercer University. School of Pharmacy. Atlanta, GA. - 2/1/2012
• Clinical Pharmacology in HIV Pre-Exposure Prophylaxis Drug Development: Developing and Applying Tools when the Train has left the Station. 
  FDA Office of Translational Science. Silver Spring, MD. - 1/1/2012
• Pharmacokinetics and Adherence in PrEP Development. 
  Forum for Collaborative HIV Research: 5th PrEP Working Group. San Francisco, CA. - 11/12/2011
• Pharmacokinetics and Tissue Concentrations of Tenofovir and Emtricitabine: What is Needed to Prevent Transmission. 
  Plenary HIV Vaccine Trials Network Annual Meeting. Seattle, WA. - 11/1/2011
• Pharmacological assessment of medication adherence – Oral PrEP and Microbicides. 
  19th International Society for STD Research. Quebec City, Canada. - 7/1/2011
• Use of Pharmacokinetics for Understanding Outcomes in HIV Prevention Trials. 
  Lab Plenary HIV Prevention Trials Network Annual Meeting, Washington, DC. - 6/1/2011
• Join now to see all

Other

• Rectal Microbicide Development: Measuring Gel & Virus Distribution. 
  Hendrix CW
  Web-Cast Teleconference, Invited Talk, International Rectal Microbicides Working Group. - 3/1/2006
• Platelet glycoprotein IIIa PIA polymorphism and effects of aspirin on thrombin generation. 
  Bray PF, Goldschmidt-Clermont P, Furman MI, Michelson AD, Barnard MR, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Kickler T, Christie DJ, Kundu S
  Letter. Response Circulation. - 2/13/2001
• AIDS in the Public Eye: AIDS Fatigue or Healthy Maturation. 
  Hendrix CW
  Lutheran AIDS Network Newsletter - 1/1/2000
• Global survey of military HIV/AIDS policies and programs. 
  Yeager R, Hendrix CW
  Civil-Military Alliance Newsletter - 1/1/1997
• Behavioral surveillance and intervention in the military environment. 
  Hendrix CW
  Civil-Military Alliance Newsletter - 1/1/1997
• Analysis of global questionnaire on HIV/AIDS prevention, testing and care in current military medical practice. 
  Kingma SJ, Hendrix CW, Yeager R, Miller NN, D’Amelio R, Wouters R
  Occasional Paper, Civil-Military Alliance to Combat HIV and AIDS - 1/1/1996
• Consideration of the prevalence of CMV retinitis alters the assessment of a serum cytomegalovirus DNA test. 
  Hendrix CW
  Letter. J Infect Dis. - 1/1/1995
• Seizing the Opportunity. HIV Prevention in Military Communities. 
  Hendrix CW
  Civil-Military Alliance Newsletter. - 1/1/1995
• Delayed-Type Hypersensitivity and AIDS. 
  Blatt SP, Hendrix CW
  Letter. Ann Intern Med. - 1/1/1994
• Join now to see all